Biopsy News and Research

RSS

Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.

Health outcomes explored at DDW 2010

Non-alcoholic fatty liver disease, which may soon be the leading indication for liver transplant, is found to be significantly associated with worse transplant outcomes. In addition, a new tool for diagnosing NAFLD represents an alternative to liver biopsy, which is more expensive and prone to complications, and ultrasound and alfafeprotein blood test screening are an effective alternative to CT scan and MRI for patients with cirrhosis at high risk for hepatocellular cancer.

3 May 2010

Vitamin E effective in treating NASH: Study

Vitamin E has been shown effective in treating nonalcoholic steatohepatitis, an obesity-associated chronic liver disease that can lead to cirrhosis, liver cancer, and death. NASH also is related to or a part of type 2 diabetes, lipid disorders and cardiovascular disease.

3 May 2010

Boston Scientific to present multiple clinical abstracts on its endoscopy products at DDW 2010

Boston Scientific Corporation today announced that multiple clinical abstracts examining the diagnostic and therapeutic utility of its SpyGlass Direct Visualization System, Radial Jaw 4 Biopsy Forceps and WallFlex Duodenal Stent will be presented at Digestive Disease Week, May 1 – 5 in New Orleans.

30 Apr 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

Study: Cigarette smoking, fructose consumption can worsen NAFLD

Recent studies suggest that modifiable risk factors such as cigarette smoking and fructose consumption can worsen nonalcoholic fatty liver disease. With NAFLD, fat accumulates in the liver of overweight individuals despite drinking little alcohol, causing in some cases liver scarring that can lead to liver failure.

27 Apr 2010

Slitrk5 gene linked to development of OCD-like behaviors

Researchers at the Ansary Stem Cell Institute and the Department of Psychiatry at Weill Cornell Medical College discovered that mice missing a single gene developed repetitive obsessive-compulsive-like behaviors. The genetically altered mice, which behaved much like people with a certain type of obsessive-compulsive disorder (OCD), could help scientists design new therapies for this debilitating condition.

27 Apr 2010

New discovery links Slitrk5 gene to development of OCD-like behaviors

27 Apr 2010

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Veran Medical Technologies announced today that it has recently completed its first installation and performed several procedures at Duke University Medical Center with its FDA-cleared SPiN Drive product. The product enables clinicians to navigate deep into the peripheral regions of the lungs to access, biopsy and treat potentially cancerous Solitary Pulmonary Nodules.

26 Apr 2010

Targeted therapy based on molecular signatures for treating lung cancer

The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported today during the American Association for Cancer Research 101st Annual Meeting 2010.

24 Apr 2010

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

Monitoring rejection in heart transplantation patients with a simple blood test co-developed by NewYork-Presbyterian Hospital/Columbia University Medical Center physician-scientist Dr. Mario Deng in 2005 can safely reduce their need for invasive heart-muscle biopsies, a new study has found.

24 Apr 2010

SuperSonic Imagine reports results of largest worldwide multicenter clinical breast study in ultrasound imaging

SuperSonic Imagine, the innovative medical imaging company based in Aix-en-Provence, France has unveiled some of the results of the largest clinical breast study ever undertaken in ultrasound imaging. The worldwide multicenter study, involving top clinicians in the breast radiology community, is assessing the clinical benefits of ShearWave™ Elastography in the ultrasonic evaluation of breast lesions.

24 Apr 2010

New blood test to determine patients at low risk for rejection of transplanted hearts

After his heart transplant in 2005, Ramon Llenado underwent a biopsy every week, then every month, then every three months. Most heart transplant patients face a lifetime of these invasive tests, which involve snipping out tiny pieces of heart to check for possible organ rejection.

23 Apr 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

Dehaier Medical Systems announces initial public offering

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical products in China, announced today its initial public offering of 1,500,000 ordinary shares at $8.00 per share. The ordinary shares will begin trading today under the ticker symbol "DHRM" on the Nasdaq Capital Market.

23 Apr 2010

Genetic tests that may replace biopsies

Genetic tests conducted on blood samples may replace the current biopsies when it comes to checking if immune systems are rejecting new organs of heart transplant patients. The test would be far less invasive and uncomfortable as compared to the biopsies, not to mention more affordable.

23 Apr 2010

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that its proprietary prostate cancer biomarker PCA3 was the topic of over 13 presentations at the 2010 European Association of Urology meeting, the world largest urology event, held in Barcelona, Spain, with 14,000 registrants.

22 Apr 2010

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA® PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.

22 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

Montgomery Breast Center of Montgomery installs GammaLoc system for biopsy procedures

The Montgomery Breast Center of Montgomery, Ala., is the first center in the country to install and use the GammaLoc lesion-localization system. This system is the only FDA-cleared device that enables gamma-guided, minimally invasive needle biopsy of suspicious lesions identified with Breast-Specific Gamma Imaging.

21 Apr 2010

Biopsy News and Research

Further Reading

Health outcomes explored at DDW 2010

Vitamin E effective in treating NASH: Study

Boston Scientific to present multiple clinical abstracts on its endoscopy products at DDW 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

Investigators study Pioglitazone and Vitamin E for treatment of NASH

Study: Cigarette smoking, fructose consumption can worsen NAFLD

Slitrk5 gene linked to development of OCD-like behaviors

New discovery links Slitrk5 gene to development of OCD-like behaviors

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Targeted therapy based on molecular signatures for treating lung cancer

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

SuperSonic Imagine reports results of largest worldwide multicenter clinical breast study in ultrasound imaging

New blood test to determine patients at low risk for rejection of transplanted hearts

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Dehaier Medical Systems announces initial public offering

Genetic tests that may replace biopsies

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Research findings may help personalize use of statins, scientists say

Montgomery Breast Center of Montgomery installs GammaLoc system for biopsy procedures

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News